EGFR and non-small cell lung carcinoma: The discovery of the oncogenic role of EGFR and the consequent development of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, afatinib, and osimertinib, revolutionized the disease history of NSCLC, markedly increasing progression-free survival (PFS) in advanced/metastatic settings [5,6,7,8,9].